Biogen Inc (BIIB)

Add to Watchlists
Create an Alert
220.25 +3.54  +1.63% NASDAQ Mar 25, 16:59 Delayed 2m USD
View Full Chart
BIIB Price Chart
View All Key Stats

BIIB Key Stats

View All BIIB News

BIIB News

View All Events

BIIB Events

Date Type Description
04/24/2019 08:30 EDT Misc Biogen Inc First Quarter Earnings Conference Call in 2019
04/24/2019 Earnings Biogen Inc First Quarter Earnings Results in 2019
02/06/2019 Misc Biogen Inc Annual Report in 2018
01/29/2019 08:00 EST Misc Biogen Inc Fourth Quarter Earnings Conference Call in 2018
01/29/2019 Earnings Biogen Inc Fourth Quarter Earnings Results in 2018
10/23/2018 08:00 EDT Misc Biogen Inc Third Quarter Earnings Conference Call in 2018
10/23/2018 Earnings Biogen Inc Third Quarter Earnings Results in 2018
07/24/2018 08:00 EDT Misc Biogen Inc Second Quarter Earnings Conference Call in 2018
07/24/2018 Earnings Biogen Inc Second Quarter Earnings Results in 2018
06/12/2018 Misc Biogen Inc Annual General Meeting in 2017
View All Performance Charts

BIIB Total Returns Comparison

BIIB Fundamentals

Income Statement View Statement

Revenue (TTM) 13.45B
Total Expenses (TTM) 7.565B
Net Income (TTM) 4.431B

Balance Sheet View Statement

Total Assets (Quarterly) 25.29B
Total Liabilities (Quarterly) 12.26B
Shareholders Equity (Quarterly) 13.04B

Cash Flow Statement View Statement

Cash from Operations (TTM) 6.188B
Cash from Investing (TTM) -2.046B
Cash from Financing (TTM) -4.472B

BIIB Ratings

Advertisement

BIIB One Page Reports

BIIB Analyst Coverage

Consensus Recommendations
Buy Recommendations Upgrade
Outperform Recommendations Upgrade
Hold Recommendations Upgrade
Underperform Recommendations Upgrade
Sell Recommendations Upgrade
Consensus Recommendation Upgrade
Consensus Rating Upgrade
Target Price
Price 220.25
Price Target Upgrade
Price Target Upside (Daily) Upgrade
Edit

Profile

  • URL: http://www.biogen.com
  • Investor Relations URL: https://www.biogen.com/en_us/investors.html
  • HQ State/Province: Massachusetts
  • Sector: Healthcare
  • Industry: Drug Manufacturers - Major
  • Equity Style: Large Cap/Blend
  • Next Earnings Release: Apr. 24, 2019
  • Last Earnings Release: Jan. 29, 2019
  • Next Ex-Dividend Date: N/A
  • Last Ex-Dividend Date: N/A
  • Description: Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Tysabri and Tecfidera. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis.

BIIB Comparables

Edit
AMGN Amgen Inc
CELG Celgene Corp
GILD Gilead Sciences Inc
IONS Ionis Pharmaceuticals Inc
JNJ Johnson & Johnson

BIIB Excel Add-In Codes

  • Name: =YCI("BIIB","name")
  • Description: =YCI("BIIB","description")
  • Sector: =YCI("BIIB","sector")
  • Industry: =YCI("BIIB","industry")
  • Est. Current Fiscal Year End: =YCI("BIIB","fye")

To find the codes for any of our financial metrics, see our Complete Reference of Metric Codes.

Access our powerful Excel Add-in with a YCharts Professional Membership. Learn More.

Other BIIB Resources

Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.

Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.